Literature DB >> 17483320

Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p.

Bao-Li Chang1, Wennuan Liu, Jishan Sun, Latchezar Dimitrov, Tao Li, Aubrey R Turner, Siqun L Zheng, William B Isaacs, Jianfeng Xu.   

Abstract

The evidence for tumor suppressor genes at 8p is well supported by many somatic deletion studies and genetic linkage studies. However, it remains a challenge to pinpoint the tumor suppressor genes at 8p primarily because the implicated regions are broad. In this study, we attempted to narrow down the implicated regions by incorporating evidence from both somatic and germline studies. Using high-resolution Affymetrix arrays, we identified two small common deleted regions among 55 prostate tumors at 8p23.1 (9.8-11.5 Mb) and 8p21.3 (20.6-23.7 Mb). Interestingly, our fine mapping linkage analysis at 8p among 206 hereditary prostate cancer families also provided evidence for linkage at these two regions at 8p23.1 (5.8-11.2 Mb) and at 8p21.3 (19.6-23.9 Mb). More importantly, by combining the results from the somatic deletion analysis and genetic linkage analysis, we were able to further narrow the regions to approximately 1.4 Mb at 8p23.1 and approximately 3.1 Mb at 8p21.3. These smaller consensus regions may facilitate a more effective search for prostate cancer genes at 8p.

Entities:  

Mesh:

Year:  2007        PMID: 17483320     DOI: 10.1158/0008-5472.CAN-06-4570

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses.

Authors:  G Bryce Christensen; Agnes B Baffoe-Bonnie; Asha George; Isaac Powell; Joan E Bailey-Wilson; John D Carpten; Graham G Giles; John L Hopper; Gianluca Severi; Dallas R English; William D Foulkes; Lovise Maehle; Pal Moller; Ros Eeles; Douglas Easton; Michael D Badzioch; Alice S Whittemore; Ingrid Oakley-Girvan; Chih-Lin Hsieh; Latchezar Dimitrov; Jianfeng Xu; Janet L Stanford; Bo Johanneson; Kerry Deutsch; Laura McIntosh; Elaine A Ostrander; Kathleen E Wiley; Sarah D Isaacs; Patrick C Walsh; William B Isaacs; Stephen N Thibodeau; Shannon K McDonnell; Scott Hebbring; Daniel J Schaid; Ethan M Lange; Kathleen A Cooney; Teuvo L J Tammela; Johanna Schleutker; Thomas Paiss; Christiane Maier; Henrik Grönberg; Fredrik Wiklund; Monica Emanuelsson; James M Farnham; Lisa A Cannon-Albright; Nicola J Camp
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

Review 2.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

3.  Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study.

Authors:  Yu Cheng; Wennuan Liu; Seong-Tae Kim; Jishan Sun; Lingyi Lu; Jielin Sun; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Cancer Genet       Date:  2011-07

4.  Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells.

Authors:  Lizheng Guo; Diansheng Zhong; Stephen Lau; Xiuju Liu; Xue-Yuan Dong; Xiaodong Sun; Vincent W Yang; Paula M Vertino; Carlos S Moreno; Vijay Varma; Jin-Tang Dong; Wei Zhou
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

5.  Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.

Authors:  Joke Beuten; Jonathan A L Gelfond; Jennifer L Franke; Stacey Shook; Teresa L Johnson-Pais; Ian M Thompson; Robin J Leach
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

6.  Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.

Authors:  X-B Shi; L Xue; A-H Ma; C G Tepper; R Gandour-Edwards; H-J Kung; R W deVere White
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

7.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Authors:  Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jishan Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jielin Sun; John T Isaacs; Bao-Li Chang; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

Review 8.  BAR the door: cancer suppression by amphiphysin-like genes.

Authors:  George C Prendergast; Alexander J Muller; Arivudanambi Ramalingam; Mee Young Chang
Journal:  Biochim Biophys Acta       Date:  2008-09-18

9.  Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.

Authors:  Yu Cheng; Jin Woo Kim; Wennuan Liu; Thomas A Dunn; Jun Luo; Matthew J Loza; Seong-Tae Kim; Siqun Lilly Zheng; Jianfeng Xu; William B Isaacs; Bao-Li Chang
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

10.  Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men.

Authors:  Joke Beuten; Jonathan A L Gelfond; Margarita L Martinez-Fierro; Korri S Weldon; AnaLisa C Crandall; Augusto Rojas-Martinez; Ian M Thompson; Robin J Leach
Journal:  Carcinogenesis       Date:  2009-06-15       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.